Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study
O Sitbon, DB Badesch, RN Channick, A Frost… - Chest, 2003 - Elsevier
Study objectives We report on the long-term safety and efficacy of bosentan treatment in
patients with pulmonary arterial hypertension (PAH). Background In a preceding study,
bosentan was well tolerated and significantly improved the exercise capacity and
hemodynamics of patients with PAH after 12 weeks of treatment. Design The present study
was an open-label extension to the preceding double-blind, placebo-controlled study of 32
patients with PAH (primary or associated with scleroderma) who received bosentan or …
patients with pulmonary arterial hypertension (PAH). Background In a preceding study,
bosentan was well tolerated and significantly improved the exercise capacity and
hemodynamics of patients with PAH after 12 weeks of treatment. Design The present study
was an open-label extension to the preceding double-blind, placebo-controlled study of 32
patients with PAH (primary or associated with scleroderma) who received bosentan or …